<DOC>
	<DOCNO>NCT02117479</DOCNO>
	<brief_summary>To determine efficacy , base upon overall survival , ruxolitinib add capecitabine treatment advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Study Ruxolitinib Pancreatic Cancer Patients ( Janus 1 )</brief_title>
	<detailed_description>This randomize , double-blinded , placebo-controlled , Phase 3 study , approximately 310 subject advance metastatic adenocarcinoma pancreas fail , intolerant first-line chemotherapy , randomize ( 1:1 ) one follow treatment group : - Treatment A ( N = 155 ) : Capecitabine + ruxolitinib - Treatment B ( N = 155 ) : Capecitabine + placebo Treatment consist repeat 21-day cycle . Capecitabine self-administered first 14 day cycle , ruxolitinib/placebo self-administered entire cycle . Treatment subject continue long regimen tolerate , subject meet discontinuation criterion . Subjects discontinue treatment continue follow subsequent anticancer treatment survival .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma pancreas . Advanced adenocarcinoma pancreas inoperable metastatic . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Received 1 prior chemotherapy regimen advance metastatic disease ( include neoadjuvant and/or adjuvant therapy ) . ≥ 2 week elapse completion previous treatment regimen subject must recover new stable baseline relate toxicity . Radiographically measurable evaluable disease An mGPS 1 2 define : Criteria : Creactive protein &gt; 10 mg/L AND albumin ≥35 g/L ; Score = 1 Creactive protein &gt; 10 mg L AND albumin &lt; 35 g/L ; Score = 2 Received 1 prior regimen advance metastatic disease . Ongoing radiation therapy , radiation therapy administer within 30 day enrollment . Concurrent anticancer therapy ( eg , chemotherapy , radiation therapy , surgery , immunotherapy , biologic therapy , hormonal therapy , investigational therapy , tumor embolization ) . Prior severe reaction fluoropyrimidines , know dihydropyrimidine dehydrogenase deficiency ( DPD ) , know hypersensitivity active substance , include fluorouracil ( 5FU ) , Ruxolitinib , excipients . Prior treatment JAK inhibitor indication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Metastatic pancreatic cancer</keyword>
	<keyword>Metastatic pancreatic adenocarcinoma recurrent</keyword>
</DOC>